Fecal Transplant Sustained Colitis Remission on Immunotherapy Resumption

Background

Immune checkpoint inhibitors (immunotherapy, ICI) can often cause adverse events, including immune-mediated colitis (IMC). Evidence that the gut microbiota may play a role in the pathogenesis and resolution of IMC is increasing. However, the long-term benefit of faecal microbiota transplant (FMT) remains to be investigated, especially in the context of ICI resumption.

purpose

We report 2 unique case patients who responded to FMT for their IMC per study protocol (Case Patient 1 in NCT03819296; Case Patient 2 in NCT04038619 did not receive steroids or biologics prior to FMT); later successfully resumed their ICI treatment; and achieved cancer remission during the study period. FMT was performed via colonoscopy using 50 g/250 ml of stool from a single healthy donor for 1 dose. Stool material was provided from the Stool Bank of the University of Texas School of Public Health.

Also Read :  Cleveland Clinic Researchers Identify Diabetes Drug Metformin as Potential Atrial Fibrillation Treatment in Collaborative Research
Patient Case 1

A 68-year-old woman with stage IV non-small cell lung cancer presented with Common Terminology criteria for adverse event grade 3 diarrhea after receiving atezolizumab for 1 year (Figure 1). Colonoscopy with biopsy showed normal mucosa consistent with chronic active colitis. Her diarrhea initially improved with a steroid taper and she was maintained on mesalamine and cholestyramine. ICI was relaunched. Diarrhea recurred 9 months later and evaluation showed erythema, friability, and exudate at endoscopy with histology demonstrating severe chronic active colitis and ulceration (Figure 2, A). ICI was withheld and IMC was managed with a steroid taper and concomitant vedolizumab, as she developed side effects of sinus congestion, leg swelling, and debilitating joint pain after a single dose. Similar symptoms recurred after switching to ustekinumab, which was discontinued. Cancer surveillance and assessment demonstrated disease progression. Given the critical need to restart ICI therapy, FMT was performed. The patient remains in clinical remission from IMC despite restarting ICI for 11 months without the need for additional diarrhea medication. A restaging scan showed remission of the cancer, and a repeat colonoscopy was normal. Faecal calprotectin decreased from an initial 227 mcg/g to 68 mcg/g at last follow-up.

Also Read :  FDA Updates for the Week of Sept. 19, 2022
Figure 1. Disease course in patient 1. The patient received atezolizumab for small cell lung cancer for 1 year until he developed immune checkpoint inhibitor colitis. Her diarrhea initially improved after steroids, which allowed her to restart atezolizumab. The diarrhea subsequently worsened and required a repeat course of steroids followed by vedolizumab infusion. He was switched to ustekinumab after an adverse reaction occurred after a single vedolizumab dose. After similar side effects developed after 2 doses of ustekinumab, faecal microbiota transplant (FMT) was performed via colonoscopy using 50 g/250 ml healthy donor stool for 1 dose (Compassionate Investigational New Drug Protocol: CIND 2021-0022). Stool material was provided from the Stool Bank of the University of Texas School of Public Health. Patients did not receive antibiotics before or after FMT for any indication. The patient was restarted atezolizumab 12 days after FMT and has been diarrhea free for 11 months after receiving 15 doses of atezolizumab. Timepoint “0” in this figure is the date of diagnosis of colitis.
Figure 2. Colonoscopy findings consistent with immune-mediated colitis. (a) Erythematous, exudative mucus. (B) Diffuse ulcerative inflammation.
Patient Case 2

A 54-year-old woman with metastatic renal cell carcinoma developed Common Terminology criteria for the adverse event grade 3 diarrhea after 5 cycles of pembrolizumab and 1 cycle of nivolumab therapy (Figure 3). Infectious work-up was negative. Faecal calprotectin was significantly increased at elevations greater than 1000 mcg/g. Colonoscopy demonstrated diffuse ulcerative inflammation (Figure 2, B). Biopsy showed chronic active colitis. FMT was performed according to the study protocol as first-line therapy for IMC. Follow-up stools improved dramatically to 78.6 mcg/g since day 1 of FMT therapy with calprotectin, the patient remaining in clinical remission. Repeat endoscopy showing ulcer healing within 2 months. He successfully resumed nivolumab and subsequently became cancer free after elective primary cancer resection at a follow-up of 7 months.

Figure 3. Disease course in patient 2. The patient received 5 cycles of pembrolizumab and 1 cycle of nivolumab therapy, after which he developed Common Terminology Criteria for Grade 3 diarrheal adverse events. He received 1 dose of faecal microbiota transplant (FMT) via colonoscopy with 50 g/250 mL of healthy donor stool from the University of Texas School of Public Health stool bank as first-line therapy for immune-mediated colitis (prospective study protocol MDA 2018-0663). . He did not receive antibiotics for any indication before or after FMT. He is in clinical remission day 1 since FMT and has successfully received 2 doses of nivolumab therapy. He also underwent surgery for the primary cancer and later achieved cancer remission. Timepoint “0” is the date of colitis diagnosis.
discussion

IMC may interfere with cancer care in patients with advanced malignancy (1). Although its management is described in oncology guidelines (2), effective strategies for keeping IMC in remission while resuming ICI have not been well studied. Ustekinumab (3) and FMT (4) are now increasingly employed as standard therapy in refractory IMC. ICI-induced microbiome dysbiosis has previously been reported as one of the potential mechanisms of IMC (5, 6). Dubin and colleagues (7) found that the prevalence of bacteria increased Phylum Bacteridetes IMC was associated with inhibition of development, which was attributed to the stimulation of regulatory T-cell differentiation by these bacteria. They also found that decreased microbial diversity was associated with increased risk of colitis (7). The first case series with successful FMT treatment of refractory IMC showed high amounts of bacterial taxa in the stools of recipients believed to be protective against IMC, including Bacteroides (4). Our case report provided further encouraging evidence that FMT has a lasting steroid-sparing therapeutic effect for IMC, which enabled the patient to recover the benefit of restarting ICI to achieve better cancer outcomes. Further microbiome analysis will provide more knowledge about the role of FMT in the treatment and maintenance of IMC.

reference

  • 1. Abu-Sebih H, Ali FS, Nakash AR, etc. Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J Clin Oncol. 2019;37:2738–45. [PMID: 31163011] doi:10.1200/JCO.19.00320 CrossrefMedlineGoogle Scholar
  • 2. Brahmar JR, Laccheti c, Snyder BJ, etc. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guidelines.. J Clin Oncol. 2018;36:1714–68. [PMID: 29442540] doi:10.1200/JCO.2017.77.6385 CrossrefMedlineGoogle Scholar
  • 3. Thomas A.S, Mother W, Wang Y. Ustekinumab for refractory colitis associated with immune checkpoint inhibitors. N Engl J Med. 2021;384:581. [PMID: 33567198] doi:10.1056/NEJMc2031717 CrossrefMedlineGoogle Scholar
  • 4. Wang Y, Wisnowski DH, Helmink BA, etc. Faecal microbiota replacement for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018;24:1804–8. [PMID: 30420754] doi:10.1038/s41591-018-0238-9 CrossrefMedlineGoogle Scholar
  • 5. Peugeot RC, Wong M, Martin A. Influence of gut microbiota on immune checkpoint inhibitor-associated toxicity. There Adv Gastroenterol. 2019;12:1756284819870911. [PMID: 31555343] doi:10.1177/1756284819870911 CrossrefMedlineGoogle Scholar
  • 6. Anderson R, Theron AJ, Report BL. Immunopathogenesis of immune checkpoint inhibitor-associated adverse events: role of the gut microbiome and Th17 cells. Frontal immunol. 2019;10:2254. [PMID: 31616428] doi:10.3389/fimmu.2019.02254 CrossrefMedlineGoogle Scholar
  • 7. Who is Dubin?, Callahan MK, Ren B, etc. Gut microbiome analysis identifies melanoma patients at risk of checkpoint-blockade-induced colitis. reduce the nat. 2016;7:10391. [PMID: 26837003] doi:10.1038/ncomms10391 CrossrefMedlineGoogle Scholar

Source

Leave a Reply

Your email address will not be published.